Clinical value of Ca-reduced phosphate binder calcium acetate Mg 2+ in the management of calcium, phosphate and secondary hyperparathyroidism;Stellenwert des kalziumreduzierten phosphatbinders kalziumacetat-Mg 2+ im kalzium-, phosphat- und sHPT-management

Nieren- und Hochdruckkrankheiten

Volumn 37, Issue 6, 2008, Pages 260-278

  Humpfner A ^a  

^a Nephrologische Gemeinschaftspraxis Mit Dialysezentrum   (Germany)

Author keywords

Calcium load; Calcium reduced phosphate binder; K DOQI Guidelines; Magnesium load; Phosphate management; Phosphate binding capacity; sHTP management

Indexed keywords

CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM MAGNESIUM ACETATE; LANTHANUM CARBONATE; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER; VITAMIN D;

BONE DISEASE; CALCIFICATION; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CLINICAL EFFECTIVENESS; DISEASE COURSE; DISEASE SEVERITY; DRUG BINDING; DRUG CONTRAINDICATION; DRUG FORMULATION; HUMAN; HYPERKALEMIA; HYPERMAGNESEMIA; HYPERPHOSPHATEMIA; MONOTHERAPY; MORBIDITY; MORTALITY; OSTEOTOXICITY; PHOSPHATE BLOOD LEVEL; REVIEW; RISK ASSESSMENT; SECONDARY HYPERPARATHYROIDISM;

EID: 47649133525     PISSN: 03005224     EISSN: None     Source Type: Journal    
DOI: 10.5414/nhp37260     Document Type: Review

References (37)

1. Ben Hamida F, el Esper I, Compagnon M, Moriniere P, Fournier A. Long-term (6 months) cross-over comparison of calcium acetate with calcium carbonate as phosphate binder. Nephron. 1993; 63: 258-262.
2. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998; 31: 607-617.
3. Block GA, Klassen P, Danese M. Association between proposed NKF-K/DOQI bone metabolism and disease guidelines and mortality risk in hemodialysis patients. Am Soc Nephrol. 2003; 14: 474A.
4. Coen D. Adynamic bone disease: an update and overview. J Nephrol. 2005; 18: 117-122.
5. Delmez JA, Kelber J, Norword KY, Giles KS, Slatopolsky E. Magnesium carbonate as a phosphorus binder: a prospective, controlled, crossover study. Kidney Int. 1996; 49: 163-167.
6. Deuber HJ, Hammerschmidt M, Bunnemann U. Wirksamkeit eines neuen kalzium- und magnesiumhaltigen Phosphatbinders bei Hämodialysepatienten. Nieren-Hochdruckkrkh. 2001; 30: 416.
7. Deuber HJ. Kombinierter Einsatz von Kalziumazetat und Magnesiumkarbonat als orale Phosphatbinder. Nieren-Hochdruckkrkh. 2004; 33: 403-408.
8. Eknoyan G, Levin A, Levin N for the National Kidney Foundation. K/DOQI-Guidelines: Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. AJKD. 2003; 42 (Suppl 3):S1-S201. Deutsche Übersetzung: www.dialyse.de/wissenschaft/k-doqi-guidelines- knochenstoffwechscl-und-renale-osteopathie-bei-chronischer-nierenerkrankung.
9. Fine KD, Santa Ana CA, Porter JL, Fordtran JS. Intestinal absorption of magnesium from food and supplements. J Clin Invest. 1991; 88: 396-402.
10. 4 product and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol. 2001; 12: 2131-2138 (2001).
11. Guerin AP, London GM, Marchais SJ et al. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000; 15: 1014-1021.
12. Guh JH, Chen HC, Chuang HY, Huang SH, Chien LC, Lai YH. Risk factors and risk for mortality of mild hypoparathyroidism in hemodialysis patients. Am J Kidney Dis. 2002; 39: 1245-1254.
13. Guillot AP, Hood VL, Runge CF, Gennari FJ. The use of magnesium-containing phosphate binders in patients with end-stage renal disease on maintenance hemodialysis. Nephron. 1982; 30: 114-117.
14. Hercz G, Pei Y, Greenwood C, Manuel A, Saiphoo C, Goodman WG, Segre GV, Fenton S, Sherrard DJ. Aplastic osteodystrophy without aluminum. The role of "suppressed" parathyroid function". Kidney Int. 1993; 43: 860-866.
15. Hümpfner A. Die adynamische Knochenerkrankung (ABD) unter Aluminiumeinfluss bei chronischer Niereninsuffizienz und Dialyse (HD, CAPD). Das Risiko der unterschätzten subklinischen Aluminiumtoxizität bei herabgesetzter Toxizitätsschwelle heute. Nieren-Hochdruckkrkh. 1996; 25: 50-71.
16. Hümpfner A. Renale Osteopathie und dialyseassoziierte Amyloidose. In: Schönweiß G (Hrsg). Dialysefibel 3, Band 1, Nüdlingen: Abakiss-Verlag; 2006. p. 254-403.
17. Hümpfner A. Diagnostik, Klinik und Behandlung der adynamen Knochenerkrankung mit/ohne Osteopenie/Osteoporose. Nieren-Hochdruckkrkh. 2007; 36: 310-332.
18. 2+. Bad Homburg: Fresenius Medical Care; 2002. p. 1-83.
19. Kovarik G. Schema zur Therapie des renalen Hyperparathyreoidismus in Anlehnung an die K/DOQI-Guidelines. Osteologie Forum. 2005;12-17.
20. Kuhlmann MK. Allgemeine Therapie der Hyperphosphatämic, www.pep-emaehrungsprogramm.de (2004).
21. Kurz P Monier-Faugere MC, Bognar B, Werner E. Roth P, Vlachojannis J, Malluche HH. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int. 1994; 46: 855-861.
22. Malluche HH, Monier-Faugere MC. Risk of adynamic bone disease in dialyzed patients. Kidney Int. 1992; 42 (Suppl 38): 62-67.
23. Marco MP, Craver L, Betriu A, Belart M, Fibla J, Fernandez E. Higher impact of mineral metabolism on cardiovascular mortality in an European hemodialysis population. Kidney Int. 2003; 63 (Suppl 85): 111-114 (2003).
24. Moriniere P, Vinatier I, Westeel PF, Cohemsolal M, Beibrik S et al. Magnesium hydroxide as a complementary aluminium-free phosphate binder to moderate doses of oral calcium in uremic patients on chronic hemodialysis: lack of deleterious effect on bone mineralization. Nephrol Dial Transplant. 1988; 3: 22-28 (1988).
25. 2. Nephron. 1992; 60: 154-163.
26. Moriniere P, Djerad M, Boudailliez B. Control of predialytic hyperphosphatemia by oral calcium acetate and calcium carbonate. Comparable efficacy for half the dose of elemental calcium given as acetate without lower incidence of hypercalcemia. Nephron. 1992; 60: 6-11.
27. ODonovan R, Parsons V. Control of hyperphosphatemia by oral magnesium carbonate on zero magnesium dialysate without aluminum binders. Proc EDTA-ERA. 1985; 22: 1229-1232.
28. O'Donovan R, Baldwin D, Hammer M, Moniz C, Parsons V. Substitution of aluminum salts by magnesium salts in control of dialysis hyperphosphatemia. Lancet. 1986; 1: 880-882.
29. Reichel H, Benzing C. Pathogenese der adynamen Osteopathie bei chronischer Niereninsuffizienz. Nieren-Hochdruckkrkh. 1999; 28: 379-385.
30. Schulz W, Deuber HJ Schulten K, Werthmann G, Delling G. Low-turnover-Osteopathie (Osteopenie) bei Patienten mit chronischer Hämodialyse. Nieren-Hochdruckkrkh. 1995; 24: 368-372.
31. Schulz W, Delling G. Adyname Knochenerkrankung (Low-turnover-Osteopathie/Osteopenie) bei chronischer Niereninsuffizienz und Dialyse. Nieren-Hochdruckkrkh. 1999; 28: 377-378.
32. Spiegel DM. The role of magnesium binders in chronic kidney disease. Semin Dial. 2007; 20: 333-336.
33. Stevens LA, Djurdjev O, Cardew S, Cameron EC, Levin A. Calcium, phosphate and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol. 2004; 15: 770-779.
34. Touyz RM. Magnesium and hypertension. Curr Opin Nephrol Hypertens. 2006; 15: 141-144.
35. Tsuchibashi K, Takizawa H, Torii T, Torii R, Ikeda R, Nakahara N et al. Hypoparathyroidism potentiates cardiovascular complications through disturbed calcium metabolism: Possible risk of vitamin D(3) analoge administration in dialysis patients with end-stage renal disease. Nephron. 2000; 84: 13-20 (2000).
36. Young EW, Satayathum S, Pisoni R, Locatelli F, Canaud B, Kurokawa K, Akiba T, Saito A, Mapes D, Port F. Prevalence of values on mineral metabolism being outside the targets from the proposed draft NKF-K/DOQI and European best practice guidelines in countries of the dialysis outcomes and practice patterns study (DOPPS). Nephrol Dial Transplant. 2003; 18 (Suppl 4): A677 (Abstract W414).
37. Zellweger U. Ersatz aluminiumhaltiger Phosphatbinder bei Langzeit-Hämodialyse-Patienten durch Kalzium- und Magnesiumcarbonat. Dtsch. Med Wochenschr. 1989; 114: 659-664.